Clinical Trial

Interstitial Cystitis: Central Autonomic Network

Study Description

Interstitial Cystitis: Examination of the Central Autonomic Network

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) afflicts 3 to 8 million women in the US. Symptoms of IC/BPS reduce quality of life, suppressing both social well-being and physical function. The chronic pain, voiding dysfunction, sleep deprivation and associated co-morbid conditions interfere with relationships and employment with significant direct (doctor visits, medication, surgery) and indirect (loss of productivity) economic impact, currently exceeding $100 million per year.This proposal aims to move the science of chronic pelvic pain (CPP) from simple associations towards an investigation of cause and effect relationships. The investigators will determine whether the striking changes in autonomic nervous system responsiveness (ANS-R) contribute meaningfully to the pathogenesis of IC/BPS.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Metoprolol Tartrate Oral Tablet

Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.

Drug - Placebo Oral Tablet

Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.

Additional Information

Official Study Title

Interstitial Cystitis: Examination of the Central Autonomic Network

Clinical Trial ID

NCT03008382

ParticipAid ID

9aAx3e